The researchers analyzed cost and sequencing-volume data from 23 FDA and FDA partner GenomeTrakr laboratories. Findings suggested that WGS-based genomic surveillance is a cost-effective public health investment.
This column will expand on the findings of the FDA study of the economic evaluation of the GenomeTrakr whole genome sequencing (WGS) program, adding data on the use of sequencing and how it will continue to change food safety practices and markets. It will also discuss what FDA is doing with GenomeTrackr to uncover previously unseen outbreaks and how this is keeping pressure on processors to expand environmental monitoring and controls.
